Antibacterial and antivirulence activities of auranofin against Clostridium difficile

Clostridium difficile is the most common hospital-acquired infectious agent [1]. C. difficile infection (CDI), also known as C. difficile associated diarrhea (CDAD), afflicted nearly half a million patients in the United States alone and was associated with over 29,000 deaths in 2011 resulting in a direct cost that exceeds $5 billion (U.S.) annually [2]. Though first discovered in the 1970s, the incidence and severity of CDI has sharply increased over the past two decades [3]. This upsurge in CDI has been attributed to the emergence of hypervirulent strains (e.g.
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Source Type: research